# Pazopanib for Metastatic Alveolar Soft Part Sarcoma

> **NCT02113826** · PHASE2 · TERMINATED · sponsor: **Seoul National University Hospital** · enrollment: 6 (actual)

## Conditions studied

- Metastatic Alveolar Soft Part Sarcoma

## Interventions

- **DRUG:** Pazopanib

## Key facts

- **NCT ID:** NCT02113826
- **Lead sponsor:** Seoul National University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-04
- **Primary completion:** 2016-09
- **Final completion:** 2017-11
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Low accrual rate
- **Last updated:** 2017-11-06

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02113826

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02113826, "Pazopanib for Metastatic Alveolar Soft Part Sarcoma". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT02113826. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*